The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

In this video, Raj Chovatiya, MD, PhD, discusses the latest findings on the use of topical roflumilast in patients with ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may contribute to conditions like obesity and heart disease, a new study suggests.

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

While short-term stress raises blood pressure temporarily, ongoing stress can lead to sustained hypertension and increase the ...

Psoriasis is often considered to be a skin condition, but it’s actually a systemic disease that can lead to symptoms such as ...

Air pollution significantly contributes to and worsens various dermatologic conditions through oxidative stress, inflammation ...